Cingulate (CING) Competitors $4.76 -0.22 (-4.42%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CING vs. CNTB, NRXP, FGEN, IMMX, GANX, VNRX, KRON, OVID, OTLK, and IOBTShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Connect Biopharma (CNTB), NRx Pharmaceuticals (NRXP), FibroGen (FGEN), Immix Biopharma (IMMX), Gain Therapeutics (GANX), VolitionRx (VNRX), Kronos Bio (KRON), Ovid Therapeutics (OVID), Outlook Therapeutics (OTLK), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Connect Biopharma NRx Pharmaceuticals FibroGen Immix Biopharma Gain Therapeutics VolitionRx Kronos Bio Ovid Therapeutics Outlook Therapeutics IO Biotech Cingulate (NASDAQ:CING) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking. Which has more volatility and risk, CING or CNTB? Cingulate has a beta of -0.84, indicating that its stock price is 184% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500. Does the MarketBeat Community prefer CING or CNTB? Connect Biopharma received 9 more outperform votes than Cingulate when rated by MarketBeat users. However, 75.00% of users gave Cingulate an outperform vote while only 72.00% of users gave Connect Biopharma an outperform vote. CompanyUnderperformOutperformCingulateOutperform Votes975.00% Underperform Votes325.00% Connect BiopharmaOutperform Votes1872.00% Underperform Votes728.00% Which has stronger valuation & earnings, CING or CNTB? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$23.53MN/AN/AConnect BiopharmaN/AN/A-$59.50MN/AN/A Do analysts rate CING or CNTB? Cingulate presently has a consensus target price of $12.00, indicating a potential upside of 152.10%. Connect Biopharma has a consensus target price of $8.00, indicating a potential upside of 672.20%. Given Connect Biopharma's higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CING or CNTB? In the previous week, Connect Biopharma had 2 more articles in the media than Cingulate. MarketBeat recorded 2 mentions for Connect Biopharma and 0 mentions for Cingulate. Connect Biopharma's average media sentiment score of 1.00 beat Cingulate's score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Cingulate Neutral Connect Biopharma Positive Is CING or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -570.20% -236.15% Connect Biopharma N/A N/A N/A Do institutionals and insiders hold more shares of CING or CNTB? 41.3% of Cingulate shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 17.1% of Cingulate shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryConnect Biopharma beats Cingulate on 9 of the 14 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.28M$6.21B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.2687.2517.09Price / SalesN/A309.921,263.9177.22Price / CashN/A61.4443.7736.04Price / Book-0.076.055.314.79Net Income-$23.53M$154.90M$122.54M$224.99M7 Day Performance3.03%1.35%1.44%2.37%1 Month Performance16.10%0.41%2.51%4.40%1 Year Performance5.31%3.08%25.32%20.10% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.4416 of 5 stars$4.76-4.4%$12.00+152.1%+5.3%$15.28MN/A0.0020Gap DownCNTBConnect Biopharma3.7679 of 5 stars$1.08-0.5%$8.00+644.2%-1.3%$59.40M$24.12M0.00110News CoveragePositive NewsHigh Trading VolumeNRXPNRx Pharmaceuticals2.8468 of 5 stars$4.91+1.2%$31.67+544.9%-90.6%$59.38MN/A-2.292Gap DownFGENFibroGen2.533 of 5 stars$0.59-4.4%N/A-24.9%$59.34M$180.02M-0.48570Gap DownIMMXImmix Biopharma3.5856 of 5 stars$2.12+1.0%$7.00+230.2%-63.2%$58.32MN/A-2.499Positive NewsGANXGain Therapeutics2.5354 of 5 stars$2.19-4.8%$7.25+231.1%-31.5%$58.09M$50,000.00-1.9920Gap UpVNRXVolitionRx1.5569 of 5 stars$0.62-4.8%$3.75+503.9%-36.7%$57.55M$1.29M-1.7280KRONKronos Bio3.2504 of 5 stars$0.95-0.6%$1.63+71.0%-2.9%$57.34M$9.86M-0.66100Positive NewsOVIDOvid Therapeutics4.7051 of 5 stars$0.80-2.0%$4.04+402.5%-76.4%$57.09M$631,695.00-1.7160Positive NewsOTLKOutlook Therapeutics2.5907 of 5 stars$2.29-3.4%$32.73+1,329.4%-68.1%$57.04MN/A-0.2120Positive NewsGap DownIOBTIO Biotech3.4384 of 5 stars$0.87-0.7%$9.33+979.0%-52.7%$56.99MN/A-0.6330Gap Up Related Companies and Tools Related Companies Connect Biopharma Competitors NRx Pharmaceuticals Competitors FibroGen Competitors Immix Biopharma Competitors Gain Therapeutics Competitors VolitionRx Competitors Kronos Bio Competitors Ovid Therapeutics Competitors Outlook Therapeutics Competitors IO Biotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CING) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
